InnVentis

How will I ever get through this day?

Big DATA, multi-omics, the internet of things: PRECISION MEDICINEThe future of health care & medicine in a connected world

Good morning Thomas! based on your PMP*

and today‘s schedule I would recommend the following diet

and supplements…

* PMP: Personal Molecular Profiles derived from longitudinal multi-omics analysis

InnVentis

2

Today’s reality - Imprecision Medicine

MDs are left with trial and error

False treatement cost: BBB US$

InnVentis

Modern diagnostics systems supported by machine learningAutomotive Status Quo

• Terabyte Data

• Precise diagnostics

• Best „treatment“ at the right time

• Reduced long term cost burden

InnVentisInflammation, a key driver of major chronic diseases

InnVentis 1st focus arthritis:

• Most Common Cause of Disability

• Affects all ages

• Cost in the U.S. $128 billion/year

Rheumatoid arthritis (RA)• 1% of the worldwide population

• Major impact on productivity

• U.S. $40 billion/year in the US

• Poorly diagnosed

• “Trial & Error” treatment decision

InnVentis

5

The Rheumatoid Arthritis diagnosis & treatment

Today: We miss the „window of opportunity“

for remission

InnVentis

From Big DATA to

Precision Medicine ?Toward Precision Medicine: Building a Knowledge Network for Biomedical Research and a New Taxonomy of Disease Committee on a Framework for Development a New Taxonomy of Disease

Preparing for Precision Medicine World Economic Forum November 2012

By 2020, four out of every five drugs launched will be Precision Medicine drugs

The precision medicine revolution: Targeted treatment zeros in on disease; GE Look ahead 2013

Precision Medicine © Dr. Thomas Wilckens, InnVentis

InnVentis

Precision Medicine - Paradigm Shift

Symptom-based Cohort-based Algorithm-based

Yesterday

Intuition Medicine

Today

Evidence-based Medicine

Tomorrow

Precision Medicine

DATA

ACTI

ON

S

Application of rules, algorithms and reference databases enables ACTIONABLE clinical decision support & PRECISE/EFFICIENT care

Reference Databases (Rules &

Algorithms)

Personal Molecular

Profiles(PMP, multi-omics)

Molecular Imaging

Non-molecular content (waveforms)

Precision Medicine

(prevention, diagnosis, treatment)

MobileInformation

CommunicationTechnologies

Big DataAnalytics

Precision Medicine © Dr. Thomas Wilckens, InnVentis

InnVentisPRECISION MEDICINE:Integrating multi-omics, clinical and real world data

Eric Topol, CELL,Volume 157, Issue 1, 27 March 2014, Pages 241–253

‘‘omic’’ Latin suffix ‘‘ome’’ = mass or many.

Creation of topological maps of health/disease

InnVentis

9

The SNYDEROME:Multi-omics, longitudinal mapping of one single person

20 different snapshots in 14-months 40K molecular parameters per blood

sample

50 Terabytes of data $2,000 each blood sample,

only reagents, not counting costs for analysis, staff, storage etc.

Costs: 10M US$

Mike Snyder, CELL, Volume 148, Issue 6, p1293–1307, 16 March 2012 Precision Medicine © Dr. Thomas Wilckens, InnVentis

InnVentis

Genome25.000 genes

Proteome1 million

Metabolome > 6000 SM

Microbiom1-3 % of

body mass

Existing knowledge ?

Big DATA

Pattern Discovery

Reference Database Machine learning

Algorithms

PersonalMolecular

Profile

Drug Molecular

Profile

Convergence of diagnostics with Big-Data & AI:Multi-omics create Personal Molecular Profile, PMP and Drug Molecular Profile

InnVentis creates & integrates standardized data in a proprietary analytics architecture.

Sample collection KIT

InnVentis

Precision Medicine & Big DATA

InnVentis enabling PRECISION MEDICINE

Precision Medicine © Dr. Thomas Wilckens

Kina’ole - "flawlessness" (Hawaian):

“Doing the right thing, in the right way, at the right time, in the right place, to the right person, for the right reason,

with the right feeling…the first time.”

InnVentis

Precision Medicine © Dr. Thomas Wilckens, InnVentis

Disease Drug 1

Molecular profiling of drug actions:Identifying responders with PMP and DMP

Drug 2 Drug 3 Remission

InnVentisGarbage in – Garbage out?Preclincial data

An analysis of past studies indicates that the cumulative (total) prevalence of irreproducible preclinical research exceeds 50%, resulting in approximately US$28,000,000,000 (US$28B)/year spent on preclinical research that is not reproducible—in the United States alone.

The Economics of Reproducibility in Preclinical Research, PLOS 2015

InnVentisGarbage in – Garbage out?Biomarker studies

Most biomarker discovery still takes place in government-funded university laboratories that are ill equipped to undertake the myriad procedures required for stringent biomarker profiling on the scale required to achieve the evidence needed to attract larger investment in clinical trials.

National Biomarker Development Alliance 9/2014

InnVentis

15

Nature Reviews Drug Discovery | 21 September 2015

Garbage in – Garbage out?Drug discovery

Tackling reproducibility in academic preclinical drug discovery

The reproducibility of biomedical research on novel drug targets has become suspect. Here, we highlight how drug discovery centres embedded in academic institutions, but with a translational imperative, can help address this reproducibility crisis.

InnVentisGarbage in – garbage out?Do Watson etc. create insight & value?

Nature 03 April 2013If a job is worth doing, it is worth doing twiceResearchers and funding agencies need to put a premium on ensuring that results are reproducible

How much existing „knowledge“ can be used, how?